Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing cancer and rare disease therapies, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 12:30 pm ET in New York. Additionally, management will join the TD Cowen 6th Annual Oncology Innovation Summit for a virtual fireside chat on May 27, 2025, at 1:30 pm ET. Both events will be webcast live and temporarily archived on the company's investor relations website.
Protara Therapeutics (Nasdaq: TARA), un'azienda in fase clinica specializzata nello sviluppo di terapie per il cancro e le malattie rare, ha annunciato la sua partecipazione a due prossimi convegni per investitori. La societ脿 prender脿 parte a una discussione informale al 3掳 Convegno Annuale BioConnect per Investitori di H.C. Wainwright & Co. il 20 maggio 2025 alle 12:30 ET a New York. Inoltre, il management parteciper脿 al 6掳 Summit Annuale sull'Innovazione in Oncologia di TD Cowen con una tavola rotonda virtuale il 27 maggio 2025 alle 13:30 ET. Entrambi gli eventi saranno trasmessi in diretta streaming e archiviati temporaneamente sul sito web delle relazioni con gli investitori della societ脿.
Protara Therapeutics (Nasdaq: TARA), una empresa en etapa cl铆nica centrada en el desarrollo de terapias para el c谩ncer y enfermedades raras, ha anunciado su participaci贸n en dos pr贸ximas conferencias para inversores. La compa帽铆a participar谩 en una charla informal en la 3陋 Conferencia Anual BioConnect para Inversores de H.C. Wainwright & Co. el 20 de mayo de 2025 a las 12:30 pm ET en Nueva York. Adem谩s, la direcci贸n participar谩 en la 6陋 Cumbre Anual de Innovaci贸n en Oncolog铆a de TD Cowen con una charla virtual el 27 de mayo de 2025 a la 1:30 pm ET. Ambos eventos ser谩n transmitidos en vivo por internet y archivados temporalmente en el sitio web de relaciones con inversores de la compa帽铆a.
Protara Therapeutics (雮橃姢雼�: TARA)電� 鞎� 氚� 頋穩歆堩櫂 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 旮办梾鞙茧, 雼り皜鞓る姅 霊� 臧滌潣 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 2025雲� 5鞗� 20鞚� 雺挫殨鞐愳劀 霃欕秬鞁滉皠 旮办 鞓ろ泟 12鞁� 30攵勳棎 鞐措Μ電� H.C. Wainwright & Co. 鞝�3須� 鞐半 BioConnect 韴瀽鞛� 旎嵓霟办姢鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂楈棎 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 霕愴暅, 瓴届榿歆勳潃 2025雲� 5鞗� 27鞚� 霃欕秬鞁滉皠 旮办 鞓ろ泟 1鞁� 30攵勳棎 臧滌禍霅橂姅 TD Cowen 鞝�6須� 鞐半 膦呾枒頃� 順侅嫚 靹滊皨鞚� 臧�靸� 韺岇澊鞏挫偓鞚措摐 毂楈棎 彀胳棳頃╇媹雼�. 霊� 頄夓偓 氇憪 靸濎瓿勲悩氅� 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐� 鞚检嫓鞝侅溂搿� 鞎勳勾鞚措笇霅╇媹雼�.
Protara Therapeutics (Nasdaq : TARA), une soci茅t茅 en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies contre le cancer et les maladies rares, a annonc茅 sa participation 脿 deux prochaines conf茅rences pour investisseurs. L'entreprise prendra part 脿 une discussion informelle lors de la 3e Conf茅rence Annuelle BioConnect pour Investisseurs de H.C. Wainwright & Co. le 20 mai 2025 脿 12h30 ET 脿 New York. De plus, la direction participera 脿 une discussion virtuelle lors du 6e Sommet Annuel d'Innovation en Oncologie de TD Cowen le 27 mai 2025 脿 13h30 ET. Les deux 茅v茅nements seront diffus茅s en direct et archiv茅s temporairement sur le site web des relations investisseurs de la soci茅t茅.
Protara Therapeutics (Nasdaq: TARA), ein klinisch fortgeschrittenes Unternehmen, das sich auf die Entwicklung von Therapien f眉r Krebs und seltene Krankheiten spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angek眉ndigt. Das Unternehmen wird am 20. Mai 2025 um 12:30 Uhr ET in New York an einem Fireside-Chat auf der 3. j盲hrlichen BioConnect-Investorenkonferenz von H.C. Wainwright & Co. teilnehmen. Zudem wird das Management am 27. Mai 2025 um 13:30 Uhr ET an einem virtuellen Fireside-Chat beim 6. j盲hrlichen Oncology Innovation Summit von TD Cowen teilnehmen. Beide Veranstaltungen werden live 眉bertragen und vor眉bergehend auf der Investor-Relations-Website des Unternehmens archiviert.
- None.
- None.
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.听(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced听that management will participate in the following investor conferences:
- H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference. A fireside chat will take place on Tuesday, May 20, 2025 at 12:30 pm ET in New York.
- TD Cowen 6th Annual Oncology Innovation Summit. A fireside chat will take place virtually on Tuesday, May 27, 2025 at 1:30 pm ET.
A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company鈥檚 website:听. The webcasts will be archived for a limited time following the presentation.
About听Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara鈥檚 portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or na茂ve to treatment with Bacillus Calmette-Gu茅rin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit听.
Company Contact:
Justine O'Malley
Protara Therapeutics
646-817-2836
FAQ
When is Protara Therapeutics (TARA) presenting at the H.C. Wainwright BioConnect Conference?
Where can I watch Protara Therapeutics' (TARA) investor conference presentations?
What type of company is Protara Therapeutics (TARA)?
When is Protara Therapeutics' (TARA) presentation at the TD Cowen Oncology Innovation Summit?
